SAM heads into its April 30 Q1 earnings report with shorts at their most aggressive in months and options traders firmly on the defensive.
Short interest is the clearest thing to watch this week. It has climbed 22% over the past month to roughly 12.5% of free float — a meaningful build in a stock that doesn't typically attract heavy short conviction. The pace has accelerated: shares short jumped more than 10% in a single week. ORTEX's short score has tracked the move up, rising from 55.7 to 59.7 over the past two weeks — not an extreme reading, but trending in a direction bears will notice. Borrow remains cheap at around 0.49%, and availability is still wide, meaning new shorts can get in without friction. This is a positioning story built around the earnings event, not a squeeze setup.
Options reinforce the cautious tone. The put/call ratio is running at 1.69, well above its 20-day average of 1.44 — roughly 1.35 standard deviations elevated, and near the upper end of its recent range. The pattern is consistent across the last two weeks: the PCR has crept from below 1.3 in early April to the current level, suggesting a gradual accumulation of downside hedges as the earnings date approached. At the same time, the 52-week high on the PCR sits at 1.94, so this isn't peak fear — just markedly more defensive than the stock's recent norm.
The Street is anchored in neutral. Citigroup raised its target to $270 on April 15, and UBS bumped its target to $250 earlier in the month — both maintaining neutral ratings rather than turning constructive. That leaves the consensus broadly flat, with the mean price target at $236, slightly below where the stock trades. The valuation sits at 22.9x trailing earnings and 9.6x EV/EBITDA, with both multiples drifting down on the week. EPS momentum scores rank in the 26th–35th percentiles — not the setup of a stock where analysts are rushing to upgrade. The bull case, per Benzinga data, centres on gross margin recovery and Twisted Tea reacceleration; the bear case points to elevated promotional spending and shortfall fees continuing to weigh on normalised margins around 49%.
Recent earnings reactions have been contained, if not inspiring. The February 2026 print saw SAM fall 2.9% the next day, though it recovered to a 0.9% gain over the following five days. The print before that — Q3 2025 results — produced a 3.6% gain on day one, followed by a 5.8% slide over the week. The pattern is asymmetric: initial reactions tend to be modest, but the five-day tape often runs harder in the downside direction. Close peers TAP and BF.B both slipped around 2–3.5% on the week, broadly in line with SAM's 2.6% decline, suggesting the softness is sector-wide rather than stock-specific.
What to watch next is straightforward: Q1 results hit after the close on April 30, and the focus will be on whether gross margin improvement — the central bull thesis — held up against tariff headwinds and any lingering Truly prepayment drag, and whether management's commentary on Twisted Tea reacceleration gives bears or bulls reason to move.
See the live data behind this article on ORTEX.
Open SAM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
